<DOC>
	<DOCNO>NCT01055535</DOCNO>
	<brief_summary>This study evaluate safety efficacy Microplasmin administer intravitreal injection , subject focal vitreomacular adhesion . Ultimately , believe intravitreal microplasmin may offer physician safe agent pharmacologic vitreolysis induction Posterior Vitreous Detachment ( PVD ) without need vitrectomy . This clinical study justify study sponsor believe potential benefit outweigh potential risk , outline .</brief_summary>
	<brief_title>Safety Efficacy Study Microplasmin Non-Surgical Treatment Focal Vitreomacular Adhesion</brief_title>
	<detailed_description />
	<mesh_term>Tissue Adhesions</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<criteria>I . Male female patient age &gt; 18 II . Presence focal vitreomacular adhesion ( ie , central vitreal adhesion within 6mm OCT field surround elevation posterior vitreous cortex III . BCVA 20/32 worse study eye IV . BCVA 20/400 good contralateral eye V. Written inform consent obtain patient prior inclusion study I . Evidence complete macular PVD study eye biomicroscopy , Bscan OCT prior plan study drug injection II . Any evidence proliferative retinopathy meeting definition PDR study eye III . Patients vitreous hemorrhage precludes either follow : visualization posterior pole visual inspection OR adequate assessment macula either OCT and/or fluorescein angiogram study eye IV . Patients rhegmatogenous retinal detachment , PVR , retinal degenerative change associate increase risk retinal detachment study eye . Such retinal degenerative change include lattice degeneration cystic retinal tuft . Thorough retinal examination perform patient rule change . V. Patients high myopia ( &gt; 8D ) aphakia study eye VI . Patients history rhegmatogenous retinal detachment fellow eye VII . Patients ocular surgery study eye prior three month VIII . Patients vitrectomy study eye time . IX . Patients glaucoma controlled topical medication associate severe visual field loss , document perimetry , study eye X . Patients laser photocoagulation treatment study eye previous 3 month XI . Intravitreal injection drug study eye previous 3 month XII . Patients pregnant childbearing potential utilizing form contraception acceptable Investigator XIII . Patients , investigator view , complete visit investigation , include last visit 6 month last injection XIV . Patients participate investigational drug study within past 30 day XV . Patients hypertension ( either SBP &gt; 170 DBP &gt; 100 mm Hg ) XVI . Patients life expectancy le 6 month XVII . Patients previously participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>